Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LETERCOR Study
2023-504384-16-00Phase 2Authorised
- Sponsor
- Fundación para la Investigación Biomédica de Córdoba
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of letermovir in cytomegalovirus disease (CMV) and Lung transplant recipient care (2 arms), sponsored by Fundación para la Investigación Biomédica de Córdoba. Primary endpoint: Incidence of CMV disease/replication for 12 months after initiation of prophylaxis. Planned start Aug 2023; status: authorised.
02
Drugs
letermovir
03
Conditions
cytomegalovirus disease (CMV)Lung transplant recipient care
Beyond the preview
Go deeper on 2023-504384-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504384-16-00.